Heavy losses persist; path to profitability claimed but unproven

Delivered revenue ₹59.7 Cr at 62.9% YoY; call claimed ₹68.6 Cr consolidated at 66% — material upside in reporting

Q1 FY27 EBITDA loss ₹25 Cr (vs ₹23.2 Cr Q1 FY26); but standalone PAT loss -₹36.3 Cr; loss per rupee of revenue worsening

Q1 AGEasy ₹19 Cr vs ₹14.6 Cr Q1 FY26 (1.3x YoY confirmed); ARR now ₹120 Cr in July per call; growth decelerating QoQ (₹23 Cr Q4 to ₹19 Cr Q1)

Occupancy rising (Bangalore 41%, Gurgaon 41%, Whitefield 18%, OMR 12%); but still requires 8-10 quarters per bed to profitability; each bed costs ₹10-12 Lakh to deploy

Possession issued June 2026; 75% of ₹169 Cr demand collected as of call date; revenue recognition deferred to Q2; Phase II approval still pending

Milestone hit: 340 units possession June 2026 (vs announced target); ASP moved from ₹7–11K to ₹16–18K Phase II pricing — margin accretion expected but hinges on Phase II approval.

Still targeting Q4 FY27 breakeven as per prior guidance; CM2 marketplace margin improving (−80% → −17% by July), but timeline unchanged; ROAS recovery trending (1-1.5 → 2.5-4) is concrete, but not front-loaded.

Occupancy inflection target pushed to Oct–Nov 2026 (unchanged from prior call); expansion decision timing stable; no acceleration in bed capacity adds.

Prior guidance was vague on geographies; now explicit: Bangalore ₹900 Cr, Dehradun ₹850–900 Cr value targets; but both in 'last stages of diligence' — announcement pending, not signed.

Prior plan: June 2026 fundraise; now deferred to unspecified date due to 'better performance' + Noida collections + credit lines. Total capex need unchanged (~₹165 Cr); but delayed raise signals slower cash burn than guided, or tighter liquidity window.

AGEasy commitment is the profitability driver; Care Homes take 8–10 quarters per bed at unit level; ASL lumpy due to DM fee timing. Revenue trajectory steady ₹175→145→190 Cr; EBITDA loss down ₹57→139→121 Cr as revenue grows. Occupancy: 5 of 8 homes trending per model; expansion decision Oct–Nov per plan.

Noida revenue booked at SPV level (JV); no revenue recognition in Q1 as recognition tied to possession, not collection. Possession Q2 → revenue Q2. Residences ₹38 Cr = DM fee ₹7 Cr + ops ₹6–7 Cr + finance lease (re-lease) ₹15 Cr + treasury ₹8 Cr.

Still on plan for doubling; July ARR at ₹120 Cr shows catch-up post-Q1 dip. 88,000 repeat customers; 10–12% repeat rate; cross-sell is where opportunity lies. ROAS is critical metric: was 1–1.5 D2C, 2.5 marketplace; now 2.5 D2C, 4 marketplace. Directionally, 20%+ repeat rate signals good space.

Core moat is services IP (engagement, wellness, integrated medicine), not infrastructure. Real estate can replicate buildings but outsource medical services — unsustainable. Hospitals have 30%+ EBITDA, won't dilute to 18% Care Homes. AGEasy moats: differentiated patents + brand; market (diaper alone ₹5,000 Cr) large enough for ₹1,000 Cr player in 5yr.

AGEasy highest ROCE (non-linear growth, jumps in ARR); Care Homes ROCE 23–24%+; ASL IRR-based targeting ₹1,800 Cr annual sales value for annuity in 2030–2033. Care Homes gets most capital (~₹10–12 Lakh per bed). Can't share FY27/28 projections; EBITDA loss trajectory (63% this year) will continue improving.

Total capex need unchanged: $25M → $20M over 2yr (capital efficiency gained). First raise was 2 tranches rights + pref; balance planned June 2026 but deferred due to better performance + Noida collections + credit lines. Received ₹40 Cr pref tranche in July. $20M incremental required next 2yr.

Not only DLF; other marquee investors also interested. DLF adding towers within existing Gurgaon township (not new); tied with Medanta Hospital. Welcome the move: drives category awareness, sets government minimum standards, benefits specialized players like us. No impact on our Gurgaon sales velocity to date.

Already at ₹120 Cr ARR in July; Q2–Q4 needs sustained ROAS + 25%+ growth; hinges on continued marketplace + D2C efficiency.

Both projects in 'last stages' diligence; Bangalore ₹900 Cr, Dehradun ₹850–900 Cr; no signed definitive agreements; announcement pending.

5 of 8 homes already trending per model; OBD up 23% QoQ; beds at ~₹10–12 Lakh capex each; scale-up dependent on continued occupancy rise.

CM2 marketplace −17% (was −80%); target: all channels CM2 positive by Q4; ROAS recovery key; timeline maintained from prior guidance.

No numerical margin target for composite Care Homes; ARPOB at ₹7,000+ in 4 homes is progress; but absolute bed-level contribution margin not quantified.

Noida Phase II higher ASP (₹16–18K) will drive profitability; but Phase II approval still pending; no specific margin guidance for ASL segment.

Was $25M; reduced to $20M due to capital efficiency gains + Noida collections. Second raise deferred but total capex need unchanged.

Q1 net loss -₹36.3 Cr; trailing 12-month EBITDA loss ₹121 Cr suggests burn ~₹10 Cr/month at segment level. Second capital raise deferred; only ₹21 Cr treasury at standalone level; $20M (~₹165 Cr) capital need over 2yr. If profitability misses further, liquidity crisis may force unplanned dilution or asset sales.

AGEasy target breakeven Q4 FY27 (Jan–Mar 2027) assumes 2–3 quarters of sustained ROAS recovery + 20%+ top-line growth. Care Homes profitability 8–10 quarters per bed (2027–2029). If ROAS plateaus or AGEasy demand softens (seasonal), breakeven pushed into FY28. If Care Homes occupancy stalls below 50%, expansion halts and cash burn accelerates.

Bangalore (₹900 Cr potential, 300 units) and Dehradun (₹850–900 Cr, 150 units) in 'last stages of diligence.' No signed definitive documents. Announcement expected 'next few months' but past delays (Chandigarh abandoned, Bangalore developer financial issues). If either project fails or gets repriced lower (₹16–18K ASP vs ₹7–11K Phase I means margin expansion only if deals signed), FY27 revenue guidance for ₹1,800 Cr missed.

10–12% repeat rate is low; 9 Lakh lives touched but only 88k repeat customers. Management acknowledges product nature (BP monitor bought once every 1–2 years) limits same-product repeats. Cross-sell is growth lever, but unclear if customers buy multiple categories. If repeat rate plateaus, growth becomes solely dependent on new customer acquisition, which is marketing-intensive (ROAS 2.5–4). Once market saturation hits, CAC rise + repeat low = unsustainable unit economics.

Occupancy rising (37→41% Bangalore, 33→41% Gurgaon) but still well below breakeven threshold (~60–70% typically needed). 485 beds at 18–41% occupancy means excess capacity cost. 8–10 quarters to bed-level profitability is aggressive; if occupancy stalls or patient attrition rises (care quality risk, family satisfaction risk), bed-level ROCE target misses. Expansion to more beds (planned post Oct–Nov inflection) compounds cash burn if occupancy doesn't sustain.

DLF announced senior living entry (within existing Gurgaon township + Medanta partnership); other RE developers and hospital chains exploring senior care. If incumbents build infrastructure scale and cross-sell to existing patient/resident bases, Max India's first-mover advantage erodes. AGEasy patent moat (4 granted, 3 filed) is narrow; e-commerce competition from large platforms (Amazon, Flipkart) can replicate products. Residential IP (integrated medicine, wellness protocols) harder to replicate but not defensible if capital + talent abundant.

Q1 experienced labor code cost inflation and geopolitical impact on China logistics (inventory cost, airlifts needed for margin-compressed products). These cost pressures are transient but recurrent. If labor costs remain high or China supply chain fragmentation persists, AGEasy COGS margin recovery stalls. Management says deflating these but no specific mitigation plan quantified.